Loading…
Based on limited metadata, this warning letter was issued to 4E Global, S.A.P.I. de C.V., a pharmaceutical company, on October 23, 2020. Without access to the full letter text or subject line, the specific nature of the drug manufacturing or distribution violations cannot be determined. The FDA's drug regulatory office issued this warning, indicating the violations related to pharmaceutical products subject to federal drug enforcement. Additional details regarding the specific compliance failures would require review of the complete warning letter.